New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: The regulatory mechanisms of cardiac innervation and their critical roles in cardiac performance

Masaki Ieda, Keiichi Fukuda

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The heart is abundantly innervated, and the nervous system precisely controls the function of this organ. The density of cardiac innervation is altered in diseased hearts, which can lead to unbalanced neural activation and lethal arrhythmia. For example, diabetic sensory neuropathy causes silent myocardial ischemia, characterized by loss of pain perception during myocardial ischemia, and it is a major cause of sudden cardiac death in diabetes mellitus. Despite the clinical importance of cardiac innervation, the mechanisms underlying the control of this process remain poorly understood. We demonstrate that cardiac innervation is determined by the balance between neural chemoattractants and chemorepellents within the heart. Nerve growth factor (NGF), a potent chemoattractant, is synthesized abundantly by cardiomyocytes, and is induced by the upregulation of endothelin-1 during development. By comparison, the neural chemorepellent Sema3a is expressed at high levels in the subendocardium in the early stage of embryogenesis and is downregulated as development progresses, leading to epicardial-to- endocardial transmural sympathetic innervation patterning. We also show that the downregulation of cardiac NGF is a cause of diabetic neuropathy and that NGF supplementation prevents silent myocardial ischemia in diabetes mellitus. Both Sema3a-targeted and Sema3a- overexpressing mice display sudden cardiac death or lethal arrhythmias due to disruption of innervation patterning. The present review focuses on the regulatory mechanisms controlling cardiac innervation and the critical roles of these processes in cardiac performance.

Original languageEnglish
Pages (from-to)348-353
Number of pages6
JournalJournal of Pharmacological Sciences
Volume109
Issue number3
DOIs
Publication statusPublished - 2009

Fingerprint

Semaphorin-3A
Nerve Growth Factor
Myocardial Ischemia
Heart Diseases
Myocardium
Diabetic Neuropathies
Sudden Cardiac Death
Chemotactic Factors
Cardiac Arrhythmias
Diabetes Mellitus
Down-Regulation
Pain Perception
Endothelin-1
Cardiac Myocytes
Nervous System
Embryonic Development
Up-Regulation

Keywords

  • Arrhythmia
  • Cardiac disease
  • Cardiac nerve
  • Nerve growth factor
  • Sema3a
  • Sudden cardiac death

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

@article{e21aa20cd1c9418bb1ff5886600150b4,
title = "New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: The regulatory mechanisms of cardiac innervation and their critical roles in cardiac performance",
abstract = "The heart is abundantly innervated, and the nervous system precisely controls the function of this organ. The density of cardiac innervation is altered in diseased hearts, which can lead to unbalanced neural activation and lethal arrhythmia. For example, diabetic sensory neuropathy causes silent myocardial ischemia, characterized by loss of pain perception during myocardial ischemia, and it is a major cause of sudden cardiac death in diabetes mellitus. Despite the clinical importance of cardiac innervation, the mechanisms underlying the control of this process remain poorly understood. We demonstrate that cardiac innervation is determined by the balance between neural chemoattractants and chemorepellents within the heart. Nerve growth factor (NGF), a potent chemoattractant, is synthesized abundantly by cardiomyocytes, and is induced by the upregulation of endothelin-1 during development. By comparison, the neural chemorepellent Sema3a is expressed at high levels in the subendocardium in the early stage of embryogenesis and is downregulated as development progresses, leading to epicardial-to- endocardial transmural sympathetic innervation patterning. We also show that the downregulation of cardiac NGF is a cause of diabetic neuropathy and that NGF supplementation prevents silent myocardial ischemia in diabetes mellitus. Both Sema3a-targeted and Sema3a- overexpressing mice display sudden cardiac death or lethal arrhythmias due to disruption of innervation patterning. The present review focuses on the regulatory mechanisms controlling cardiac innervation and the critical roles of these processes in cardiac performance.",
keywords = "Arrhythmia, Cardiac disease, Cardiac nerve, Nerve growth factor, Sema3a, Sudden cardiac death",
author = "Masaki Ieda and Keiichi Fukuda",
year = "2009",
doi = "10.1254/jphs.08R25FM",
language = "English",
volume = "109",
pages = "348--353",
journal = "Journal of Pharmacological Sciences",
issn = "1347-8613",
publisher = "Japanese Pharmacological Society",
number = "3",

}

TY - JOUR

T1 - New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles

T2 - The regulatory mechanisms of cardiac innervation and their critical roles in cardiac performance

AU - Ieda, Masaki

AU - Fukuda, Keiichi

PY - 2009

Y1 - 2009

N2 - The heart is abundantly innervated, and the nervous system precisely controls the function of this organ. The density of cardiac innervation is altered in diseased hearts, which can lead to unbalanced neural activation and lethal arrhythmia. For example, diabetic sensory neuropathy causes silent myocardial ischemia, characterized by loss of pain perception during myocardial ischemia, and it is a major cause of sudden cardiac death in diabetes mellitus. Despite the clinical importance of cardiac innervation, the mechanisms underlying the control of this process remain poorly understood. We demonstrate that cardiac innervation is determined by the balance between neural chemoattractants and chemorepellents within the heart. Nerve growth factor (NGF), a potent chemoattractant, is synthesized abundantly by cardiomyocytes, and is induced by the upregulation of endothelin-1 during development. By comparison, the neural chemorepellent Sema3a is expressed at high levels in the subendocardium in the early stage of embryogenesis and is downregulated as development progresses, leading to epicardial-to- endocardial transmural sympathetic innervation patterning. We also show that the downregulation of cardiac NGF is a cause of diabetic neuropathy and that NGF supplementation prevents silent myocardial ischemia in diabetes mellitus. Both Sema3a-targeted and Sema3a- overexpressing mice display sudden cardiac death or lethal arrhythmias due to disruption of innervation patterning. The present review focuses on the regulatory mechanisms controlling cardiac innervation and the critical roles of these processes in cardiac performance.

AB - The heart is abundantly innervated, and the nervous system precisely controls the function of this organ. The density of cardiac innervation is altered in diseased hearts, which can lead to unbalanced neural activation and lethal arrhythmia. For example, diabetic sensory neuropathy causes silent myocardial ischemia, characterized by loss of pain perception during myocardial ischemia, and it is a major cause of sudden cardiac death in diabetes mellitus. Despite the clinical importance of cardiac innervation, the mechanisms underlying the control of this process remain poorly understood. We demonstrate that cardiac innervation is determined by the balance between neural chemoattractants and chemorepellents within the heart. Nerve growth factor (NGF), a potent chemoattractant, is synthesized abundantly by cardiomyocytes, and is induced by the upregulation of endothelin-1 during development. By comparison, the neural chemorepellent Sema3a is expressed at high levels in the subendocardium in the early stage of embryogenesis and is downregulated as development progresses, leading to epicardial-to- endocardial transmural sympathetic innervation patterning. We also show that the downregulation of cardiac NGF is a cause of diabetic neuropathy and that NGF supplementation prevents silent myocardial ischemia in diabetes mellitus. Both Sema3a-targeted and Sema3a- overexpressing mice display sudden cardiac death or lethal arrhythmias due to disruption of innervation patterning. The present review focuses on the regulatory mechanisms controlling cardiac innervation and the critical roles of these processes in cardiac performance.

KW - Arrhythmia

KW - Cardiac disease

KW - Cardiac nerve

KW - Nerve growth factor

KW - Sema3a

KW - Sudden cardiac death

UR - http://www.scopus.com/inward/record.url?scp=67249097409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67249097409&partnerID=8YFLogxK

U2 - 10.1254/jphs.08R25FM

DO - 10.1254/jphs.08R25FM

M3 - Article

C2 - 19270423

AN - SCOPUS:67249097409

VL - 109

SP - 348

EP - 353

JO - Journal of Pharmacological Sciences

JF - Journal of Pharmacological Sciences

SN - 1347-8613

IS - 3

ER -